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Background: “Mapping” onto generic preference-based outcome measures is increasingly being used as a means of generating health utilities for use within health economic
evaluations. Despite publication of technical guides for the conduct of mapping research, guidance for the reporting of mapping studies is currently lacking. The MAPS (MApping onto
Preference-based measures reporting Standards) statement is a new checklist, which aims to promote complete and transparent reporting of mapping studies.
Methods: In the absence of previously published reporting checklists or reporting guidance documents, a de novo list of reporting items was created by a working group comprised of
six health economists and one Delphi methodologist. A two-round, modified Delphi survey with representatives from academia, consultancy, health technology assessment agencies,
and the biomedical journal editorial community was used to identify a list of essential reporting items from this larger list.
Results: From the initial de novo list of twenty-nine candidate items, a set of twenty-three essential reporting items was developed. The items are presented numerically and
categorized within six sections, namely: (i) title and abstract, (ii) introduction, (iii) methods, (iv) results, (v) discussion, and (vi) other. The MAPS statement is best applied in
conjunction with the accompanying MAPS explanation and elaboration document.
Conclusions: It is anticipated that the MAPS statement will improve the clarity, transparency. and completeness of reporting of mapping studies. To facilitate dissemination and
uptake, the MAPS statement is being co-published by seven health economics and quality of life journals, and broader endorsement is encouraged. The MAPS working group plans to
assess the need for an update of the reporting checklist in five years’ time.
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The process of “mapping” onto generic preference-based out-
come measures is increasingly being used as a means of gen-
erating health utilities for application within health economic
evaluations (1). Mapping involves the development and use of
an algorithm (or algorithms) to predict the primary outputs of
generic preference-based outcome measures, i.e., health utility
values, using data on other indicators or measures of health.
The source predictive measure may be a non–preference-based
indicator or measure of health outcome or, more exceptionally, a
preference-based outcome measure that is not preferred by the
local health technology assessment agency. The algorithm(s)
can subsequently be applied to data from clinical trials, ob-
servational studies, or economic models containing the source
predictive measure(s) to predict health utility values in contexts
where the target generic preference-based measure is absent.
The predicted health utility values can then be analyzed using
standard methods for individual-level data (e.g., within a trial-
based economic evaluation), or summarized for each health
state within a decision-analytic model.
Over recent years, there has been a rapid increase in the pub-
lication of studies that use mapping techniques to predict health
utility values, and databases of published studies in this field are
beginning to emerge (2). Some authors (3) and agencies (4) con-
cerned with technology appraisals have issued technical guides
for the conduct of mapping research. However, guidance for the
reporting of mapping studies is currently lacking. In keeping
with health-related research more broadly (5), mapping studies
should be reported fully and transparently to allow readers to as-
sess the relative merits of the investigation (6). Moreover, there
may be significant opportunity costs associated with regulatory
and reimbursement decisions for new technologies informed by
misleading findings from mapping studies. This has led to the
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development of the MAPS (MApping onto Preference-based
measures reporting Standards) reporting statement, which we
summarize in this study.
The aim of the MAPS reporting statement is to provide
recommendations, in the form of a checklist of essential items,
which authors should consider when reporting a mapping study.
It is anticipated that the checklist will promote complete and
transparent reporting by researchers. The focus, therefore, is
on promoting the quality of reporting of mapping studies,
rather than the quality of their conduct, although it is possi-
ble that the reporting statement will also indirectly enhance the
methodological rigor of the research (7). The MAPS report-
ing statement is primarily targeted at researchers developing
mapping algorithms, the funders of the research, and peer re-
viewers and editors involved in the manuscript review process
for mapping studies (5;6). In developing the reporting state-
ment, the term “mapping” is used to cover all approaches that
predict the outputs of generic preference-based outcome mea-
sures using data on other indicators or measures of health, and
encompasses related forms of nomenclature used by some re-
searchers, such as “cross-walking” or “transfer to utility” (1;8).
Similarly, the term “algorithm” is used in its broadest sense to
encompass statistical associations and more complex series of
operations.
DEVELOPMENT OF THE MAPS STATEMENT
The development of the MAPS reporting statement was in-
formed by recently published guidance for health research re-
porting guidelines (5) and broadly modeled other recent report-
ing guideline developments (9–14). Aworking group comprised
of six health economists (S.P., O.R.A., H.D., L.L., M.O., A.G.)
and one Delphi methodologist (R.F.) was formed following a
request from an academic journal to develop a reporting state-
ment for mapping studies. One of the working group members
(H.D.) had previously conducted a systematic review of studies
mapping from clinical or health-related quality of life measures
onto the EQ-5D (2). Using the search terms from this system-
atic review, as well as other relevant articles and reports already
in our possession, a broad search for reporting guidelines for
mapping studies was conducted. This confirmed that no previ-
ous reporting guidance had been published. The working group
members, therefore, developed a preliminary de novo list of
twenty-nine reporting items and accompanying explanations.
Following further review by the working group members, this
was subsequently distilled into a list of twenty-five reporting
items and accompanying explanations.
Members of theworking group identified sixty-two possible
candidates for a Delphi panel from a pool of active researchers
and stakeholders in this field. The candidates included indi-
viduals from academic and consultancy settings with consid-
erable experience in mapping research, representatives from
health technology assessment agencies that routinely appraise
evidence informed by mapping studies, and biomedical journal
editors. Health economists from theMAPSworking group were
included in the Delphi panel. A total of forty-eight of the sixty-
two (77.4 percent) individuals agreed to participate in a Delphi
survey aimed at developing a minimum set of standard report-
ing requirements for mapping studies with an accompanying
reporting checklist.
TheDelphi panelists were sent a personalized link to aWeb-
based survey, which had been piloted by members of the work-
ing group. Nonresponders were sent up to two reminders after
14 and 21 days. The panelists were anonymous to each other
throughout the study and their identities were known only to one
member of the working group. The panelists were invited to rate
the importance of each of the twenty-five candidate reporting
items identified by the working group on a 9-point rating scale
(1, “not important”, to 9, “extremely important”); describe their
confidence in their ratings (“not confident,” “somewhat confi-
dent,” or “very confident”); comment on the candidate items
and their explanations; suggest additional items for considera-
tion by the panelists in subsequent rounds; and to provide any
other general comments. The candidate reporting items were
ordered within six sections: (i) title and abstract, (ii) introduc-
tion, (iii) methods, (iv) results, (v) discussion, and (vi) other.
The panelists also provided information about their geograph-
ical area of work, gender, and primary and additional work
environments. The data were imported into Stata (version 13;
Stata-Corp, College Station, TX) for analysis.
A modified version of the Research ANd Development
(RAND)/ University of California Los Angeles (UCLA) appro-
priateness method was used to analyze the round one responses
(15). This involved calculating the median score, the inter-
percentile range (IPR) (30th and 70th), and the inter-percentile
range adjusted for symmetry (IPRAS), for each item (i) being
rated. The IPRAS includes a correction factor for asymmet-
ric ratings, and panel disagreement was judged to be present
in cases if IPRi>IPRASi (15). We modified the RAND/UCLA
approach by asking panelists about “importance” rather than
“appropriateness” per se. Assessment of importance followed
the classic RAND/UCLA definitions, categorized simply as
whether the median rating fell between 1 and 3 (unimportant),
4 and 6 (neither unimportant nor important), or 7 and 9 (impor-
tant) (15).
The results of round one of the Delphi surveywere reviewed
at a face-to-face meeting of the working group. A total of forty-
six of the forty-eight (95.8 percent) individuals who agreed to
participate completed round one of the survey. Of the twenty-
five items, twenty-four were rated as important, with one item
(“Source of Funding”) rated as neither unimportant nor im-
portant. There was no evidence of disagreement on ratings of
any items according to the RAND/UCLA method. These find-
ings did not change when the responses of the MAPS working
group were excluded. Based on the qualitative feedback re-
ceived in round one, items describing “Modelling Approaches”
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 31:4, 2015 2
The MAPS Reporting Statement
and “Repeated Measurements” were merged, as were items
describing “Model Diagnostics” and “Model Plausibility.” In
addition, amendments to the wording of several recommenda-
tions and their explanations were made in the light of qualitative
feedback from the panelists.
Panelists participating in round one were invited to par-
ticipate in a second round of the Delphi survey. A summary
of revisions made following round one was provided. This in-
cluded a document in which revisions to each of the recommen-
dations and explanations were displayed in the form of track
changes. Panelists participating in round two were provided
with group outputs (mean scores and their standard deviations,
median scores and their IPRs, histograms and RAND/UCLA la-
bels of importance and agreement level) summarizing the round
one results (and disaggregated outputs for the merged items).
They were also able to view their own round one scores for each
item (and disaggregated scores for the merged items). Panelists
participating in round twowere offered the opportunity to revise
their rating of the importance of each of the items and informed
that their rating from round one would otherwise hold. For the
merged items, new ratings were solicited. Panelists participat-
ing in round two were also offered the opportunity to provide
any further comments on each item or any further information
that might be helpful to the group. Nonresponders to the second
round of the Delphi survey were sent up to two reminders after
14 and 21 days. The analytical methods for the round two data
mirrored those for the first round.
The results of the second round of the Delphi survey were
reviewed at a face-to-face meeting of the working group. A
total of thirty-nine of the forty-six (84.8 percent) panelists par-
ticipating in round one completed round two of the survey. All
twenty-three items included in the second round were rated as
important with no evidence of disagreement on ratings of any
items according to the RAND/UCLAmethod. Qualitative feed-
back from the panelists participating in round two led to minor
modifications to wording of a small number of recommenda-
tions and their explanations. This was fed back to the round
two respondents who were given a final opportunity to com-
ment on the readability of the final set of recommendations and
explanations. Based on these methods, a final consensus list of
twenty-three reporting items was developed.
THE MAPS STATEMENT
The MAPS statement is a twenty-three item checklist of rec-
ommendations (Table 1) that we consider essential for com-
plete and transparent reporting of studies that map onto generic
preference-based outcome measures. The twenty-three report-
ing items are presented numerically and categorized within six
sections, namely: (i) title and abstract (two items). (ii) intro-
duction (two items). (iii) methods (nine items). (iv) results (six
items). (v) discussion (three items). and (vi) other (one item).
The reporting of each item does not necessarily have to follow
the order within the MAPS statement. Rather, what is important
is that each recommendation is addressed either in the main
body of the report or its appendices. Several biomedical jour-
nals have endorsed theMAPS statement. These include Applied
Health Economics andHealth Policy,Health andQuality of Life
Outcomes, International Journal of Technology Assessment in
Health Care, Journal of Medical Economics,Medical Decision
Making, PharmacoEconomics, and Quality of Life Research.
We encourage other journals and research interest groups to
endorse the MAPS statement and authors to adhere to its prin-
ciples.
MAPS EXPLANATION AND ELABORATION PAPER
In addition to the MAPS reporting statement, we have pro-
duced a supporting Explanation and Elaboration paper (16),
modeled on those developed for other reporting guidelines (9–
14). The reporting items contained within the MAPS state-
ment are best understood by referring to the information con-
tained within this accompanying document. The Explanation
and Elaboration paper provides exemplars of good reporting
practice identified from the published literature for each re-
porting item. In addition, it provides a detailed explanation
to accompany each recommendation, supported by a rationale
and relevant evidence where available. The development of the
Explanation and Elaboration paper was completed following
several iterations produced by members of the working group,
after which the examples and explanations were shared with
the Delphi panelists for final revisions to improve readabil-
ity and their approval. The Explanation and Elaboration pa-
per also summarizes the characteristics of the Delphi panelists
and provides detailed statistics for item ratings at each Delphi
round.
DISCUSSION
Over recent years, there has been a rapid increase in the
publication of studies that use mapping techniques to pre-
dict health utility values. One recent review article identified
ninety studies published up to the year 2013 reporting 121
mapping algorithms between clinical or health-related qual-
ity of life measures and the EQ-5D (2). That review arti-
cle excluded mapping algorithms targeted at other generic
preference-based outcome measures that can generate health
utilities, such as the SF-6D (17) and the Health Utilities In-
dex (HUI) (18), which have been the target of numerous other
mapping algorithms (e.g., 1;19–24). Moreover, the popularity
of the mapping approach for estimating health utilities is un-
likely to wane, given the numerous contexts within health eco-
nomic evaluation where primary data collection is challenging.
However, mapping introduces additional uncertainty and col-
lection of primary data with the preferred utility instrument is
preferable.
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Table 1. Checklist of Items to Include When Reporting a Mapping Study
Section/topic Item number Recommendation Reported on page number/ line number
Title and abstract
Title 1 Identify the report as a study mapping between outcome measures. State
the source measure(s) and generic, preference-based target measure(s)
used in the study.
_____________
Abstract 2 Provide a structured abstract including, as applicable: objectives; methods,
including data sources and their key characteristics, outcome measures used
and estimation and validation strategies; results, including indicators of
model performance; conclusions; and implications of key findings.
_____________
Introduction
Study rationale 3 Describe the rationale for the mapping study in the context of the broader
evidence base.
_____________
Study objective 4 Specify the research question with reference to the source and target
measures used and the disease or population context of the study.
_____________
Methods
Estimation sample 5 Describe how the estimation sample was identified, why it was selected, the
methods of recruitment and data collection, and its location(s) or setting(s).
_____________
External validation sample 6 If an external validation sample was used, the rationale for selection, the
methods of recruitment and data collection, and its location(s) or setting(s)
should be described.
____________
Source and target measures 7 Describe the source and target measures and the methods by which they
were applied in the mapping study.
_____________
Exploratory data analysis 8 Describe the methods used to assess the degree of conceptual overlap
between the source and target measures.
_____________
Missing data 9 State how much data were missing and how missing data were managed
in the sample(s) used for the analyses.
_____________
Modelling approaches 10 Describe and justify the statistical model(s) used to develop the mapping
algorithm.
_____________
Estimation of predicted scores or utilities 11 Describe how predicted scores or utilities are estimated for each model
specification.
_____________
Validation methods 12 Describe and justify the methods used to validate the mapping algorithm. _____________
Measures of model performance 13 State and justify the measure(s) of model performance that determine the
choice of the preferred model(s) and describe how these measures were
estimated and applied.
_____________
Results
Final sample size(s) 14 State the size of the estimation sample and any validation sample(s) used
in the analyses (including both number of individuals and number of
observations).
_____________
Descriptive information 15 Describe the characteristics of individuals in the sample(s) (or refer back to
previous publications giving such information). Provide summary scores for
source and target measures, and summarize results of analyses used to
assess overlap between the source and target measures.
_____________
Model selection 16 State which model(s) is(are) preferred and justify why this(these)
model(s) was(were) chosen.
_____________
Model coefficients 17 Provide all model coefficients and standard errors for the selected model(s).
Provide clear guidance on how a user can calculate utility scores based on
the outputs of the selected model(s).
_____________
Uncertainty 18 Report information that enables users to estimate standard errors around
mean utility predictions and individual-level variability.
_____________
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Table 1. Continued.
Section/topic Item number Recommendation Reported on page number/ line number
Model performance and face validity 19 Present results of model performance, such as measures of prediction
accuracy and fit statistics for the selected model(s) in a table or in the text.
Provide an assessment of face validity of the selected model(s).
_____________
Discussion
Comparisons with previous studies 20 Report details of previously published studies developing mapping
algorithms between the same source and target measures and describe
differences between the algorithms, in terms of model performance,
predictions and coefficients, if applicable.
_____________
Study limitations 21 Outline the potential limitations of the mapping algorithm. _____________
Scope of applications 22 Outline the clinical and research settings in which the mapping algorithm
could be used.
_____________
Other
Additional information 23 Describe the source(s) of funding and non-monetary support for the study,
and the role of the funder(s) in its design, conduct and report. Report any
conflicts of interest surrounding the roles of authors and funders.
_____________
The MAPS reporting statement was developed to pro-
vide recommendations, in the form of a checklist of essential
items, which authors should consider when reporting mapping
studies. Guidance for the reporting of mapping studies was not
previously available in the literature. The overall aim of MAPS
is to promote clarity, transparency, and completeness of report-
ing of mapping studies. It is not intended to act as a method-
ological guide, nor as a tool for assessing the quality of study
methodology. Rather, it aims to avoid misleading conclusions
being drawn by readers, and ultimately policy makers, as a
result of sub-optimal reporting. In keeping with other recent
health research reporting guidelines, we have also produced an
accompanying Explanation and Elaboration paper (16) to facil-
itate a deeper understanding of the twenty-three items contained
within the MAPS reporting statement. That paper should hope-
fully act as a pedagogical framework for researchers reporting
mapping studies.
The development of the MAPS reporting statement, and its
Explanation and Elaboration document, was framed by recently
published guidance for health research reporting guidelines (5).
The Delphi panel was composed of a multi-disciplinary, multi-
national team of content experts and journal editors. The panel
members included people experienced in conducting mapping
studies; of the eighty-four researchers who were first authors
on papers included in a recent review of EQ-5D mapping stud-
ies (2), thirty-one (36.9 percent) were included as panelists.
We have no evidence to believe that a larger panel would have
altered the final set of recommendations. The Delphi method-
ologies that we applied included analytical approaches only
recently adopted by developers of health reporting guidelines
(15). We are unable to assess whether a strict adherence to
the MAPS checklist will increase the word counts of mapping
reports. It is our view that the increasing use of online ap-
pendices by journals should permit comprehensive reporting
even in the context of strict word limits for the main body of
reports.
Evidence for other health research reporting guidelines sug-
gests that reporting quality improved after the introduction of
reporting checklists (25–27), although there is currently no em-
pirical evidence that adoption of MAPS will improve the qual-
ity of reporting of mapping research. Future research planned
by the MAPS working group will include a before and after
evaluation of the benefits (and indeed possible adverse effects)
of the introduction of the MAPS reporting statement. It will
also be necessary to update the MAPS reporting statement in
the future to address conceptual, methodological, and practical
advances in the field. Potential methodological advances that
might be reflected in an update might include shifts toward
more complex model specifications, better methods for dealing
with uncertainty, and guidance on appropriate use of measures
of prediction accuracy, such as mean absolute error (MAE) and
mean square error (MSE). The MAPS working group plans to
assess the need for an update of the reporting checklist in 5
years’ time.
In conclusion, this study summarizes a new reporting state-
ment developed for studies that map onto generic preference-
based outcome measures. We encourage health economic and
quality of life journals to endorseMAPS, promote its use in peer
review and update their editorial requirements and “Instructions
to Authors” accordingly.
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